Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics and therapies of patients with eosinophilic granulomatosis with polyangiitis (EGPA) or chronic eosinophilic pneumonia (CEP)

From: Th17 cells reflect colon submucosal pathologic changes in active eosinophilic granulomatosis with polyangiitis

  EGPA patients (n = 17) CEP patients (n = 12) P
Age (y), mean ± 1 SD 41.8 ± 15.9 44.2 ± 17.0 NSa
Sex (M/F) 7/10 6/6 NSb
Type: atopy/nonatopy 8/9 4/8 NSb
Allergic rhinitis (yes/no) 9/7 7/5 NSb
Atopic dermatitis (yes/no) 4/13 2/10 NSb
Age at onset asthma (y), mean ± SD 34.5 ± 14.3 36.3 ± 14.4 NSa
Astham severity Step 1/2/3/4 1/0/5/11 2/0/3/8 NSb
Daily dose of ICS (mg; converted to CFC-BDP equivalents) 1482.4 ± 656.0 1173.3 ± 812.3 NSa
Organ involvement at onset of EGPA or CEP patients (%)
 Asthma 100 100 NSb
 Paranasal sinusitis 94.1 83.3 NSb
 Multiple polyneuropathy 100 0 <0.01b
 Pulmonary infiltrates 88.2 100 NSb
 Myocardinal involvement 76.5 0 <0.01b
 Liver, gall bladder, pancreas 17.6 0 NSb
 Renal involvementc 41.2 0 < 0.05b
  Proteinuria 41.2 0 < 0.05b
  Nephritis or nephrosis 11.8 0 NSb
 Skin involvement 88.2 25 < 0.01b
 Arthritis 52.9 0 < 0.01b
 Myalgia 29.4 0 < 0.05b
 Central nervous system involvement 29.4 0 < 0.05b
Gastrointestinal tract
 Clinical symptoms on the upper abdominal region (yes/no) 10/7 3/9 NSb
 Clinical symptoms on the lower abdominal region (yes/no) 12/5 8/4 NSb
 Positive signs on mucous membrane of the upper digestive organs by stomach endscope (yes/no) 10/7 2/10 < 0.05b
 Positive signs on mucous membrane of the large intestine by colon endscope (yes/no) 8/9 5/7 NSb
 Treatment for EGPA or CEP
 Systemic corticosteroids (yes/no) 17/0 5/7 < 0.01b
 Prednisolone per day for initial dose (mg), mean ± 1 SD 45.5 ± 10.7 20.2 ± 5.5 < 0.01a
 Patients taking an immunosuppressant (%) 76.5 0 < 0.01b
 CYC/AZA/CSA 6/3/4 0/0/0  
 IVIG (yes/no) 9/8 0/12 < 0.01b
  1. AZA azathioprine, CFC-BDP chlorofluorocarbon-propelled beclomethasone dipropionate, CSA ciclosporin, CYC cyclophosphamide, ICS inhaled corticosteroid, IVIG intravenous immunoglobulin, NS not significant
  2. All values are expressed as means ± 1 SD
  3. Values of P < 0.05 were considered statistically significant
  4. aTwo-way ANOVA employing a repeated-measures test to explore the significance of differences between any two groups
  5. bChi-squared testing revealed no significant differences in frequency between the two groups
  6. cRenal involvement including protein uria or eosinophils in urin or glomerular nephritis or nephrosis or renal dysfunction
  7. Asthma severity was according to GINA guide lines